Licoforte 4%

Quick links to important sections

Licoforte 4%

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Licoforte 4%

Quick Facts: Licoforte 4%

Property Description
Active Ingredient Hydroquinone (Benzene-1,4-diol)
Form Cream, Topical Solution, or Gel
Pharmacological Class Depigmenting Agent, Melanin Synthesis Inhibitor
Common Use Lightening hyperpigmented skin areas
Origin Synthetic, Small Molecule Compound

What is Licoforte 4% and Its Primary Composition?

Licoforte 4% is a specialized topical pharmaceutical preparation intended for cutaneous use, containing the active ingredient Hydroquinone. The product's identity is centered on its 4% concentration, which is widely clinically recognized as a standard strength for depigmenting preparations, delivering 40 mg of Hydroquinone per gram of base. The compound Hydroquinone itself is a synthetic organic compound and is typically incorporated into a suitable vehicle, such as an emulsion-based cream, gel, or topical solution base, for effective delivery into the skin layers.


What Type of Drug is Licoforte 4%?

Licoforte 4% is officially classified in the Pharmacological Class of Depigmenting Agents, specifically functioning as a Melanin Synthesis Inhibitor. This classification confirms that the drug's therapeutic action is rooted in chemically intervening with the skin's coloring process. This high-strength, single-active compound is often positioned for dedicated dermatological use against severe or persistent discoloration due to its potent, targeted action. Its core mechanism involves inhibiting the specific enzyme, tyrosinase, which is essential for initiating the creation of melanin.


What is the General Purpose of Licoforte 4%?

The general purpose of this topical formulation is to achieve reversible depigmentation for the gradual lightening and evening out of affected skin areas. By slowing the production of new pigment at the cellular level, the preparation enables the skin to replace existing dark cells with newly formed, lighter ones. This action provides a targeted approach to reduce visible skin discoloration associated with various forms of hyperpigmentation disorders.

Regulatory References

  1. Hydroquinone 4% Cream official drug label (DailyMed/NIH)

What side effects are possible with Licoforte 4%?

Possible Side Effects and Safety Information

The safety profile for Licoforte 4% (topical hydroquinone) is predominantly characterized by localized skin reactions and is defined by specific regulatory warnings concerning chronic use and hypersensitivity, as documented in official government labeling.


Documented Adverse Reactions

Classification Examples of Effects Context and Frequency
Common Local Reactions Erythema (redness), stinging, dryness, and mild burning sensation These effects are frequently reported but often lack formal frequency classification in regulatory documents.
Occasional Reactions Localized contact dermatitis and cutaneous hypersensitivity reactions. These are documented reactions that occur less frequently than common local reactions.

Serious Adverse Reactions and Safety Constraints

Official labeling mandates attention to two critical safety issues. The first is Exogenous Ochronosis, a serious adverse reaction defined as a gradual, potentially permanent blue-black darkening of the skin that may be associated with chronic, long-term use. The development of Ochronosis requires treatment discontinuation, as advised by regulatory authorities. The second key risk involves severe allergic-type reactions, including anaphylactic symptoms, linked to the preservative sodium metabisulfite present in some formulations.

Safety Constraint Regulatory Statement (High-Level)
Contraindication The product is contraindicated in any individual with a prior history of sensitivity or allergy to hydroquinone or any formulation ingredients.
Special Populations Safety and effectiveness have not been established for pediatric patients below 12 years of age.
Exposure Limitation Strict avoidance of unnecessary solar exposure is required during treatment, as sunlight sustains the activity that can reverse the depigmenting effect.

These constraints establish the official safety boundaries for use, limiting administration based on age, pre-existing sensitivities, and the necessary control of external exposure.

Overdose and Emergency Response

Licoforte 4% Overdose and When to Seek Help

This section summarizes the official regulatory information regarding overdosage with Licoforte 4%, defining the documented clinical consequences and mandated emergency response.

Regulatory Entity Official Information Summary (Label-Based)
Documented Overdose Manifestations Specific signs, symptoms, and laboratory findings associated with overdosage, based on clinical or supported non-human data, including the onset of systemic toxicity or pronounced adverse effects.
Serious / Life-Threatening Outcomes The officially documented severe complications, such as major organ dysfunction, profound central nervous system depression, or cardiovascular instability, that are likely to be life-threatening.
Emergency-Response Statements Explicit, non-advisory instructions that mandate immediate discontinuation of the drug and transportation to a medical facility or contacting a national certified Poison Control Center.
Antidotal and Supportive Measures Recommended general treatment procedures and specific measures for the support of vital functions, including any proven antidote or reversal agent and methods to enhance drug elimination (e.g., dialysis), as defined by the regulator.

When to Seek Urgent Medical Help (Label-Derived Phrasing Only):

Immediate medical help must be sought, or a certified poison control center contacted, if an overdosage is known or strongly suspected. This action is required regardless of the presence or severity of symptoms due to the risk of delayed or escalating life-threatening manifestations.

Connection to the Overall Overdose Profile:

The official regulatory documents establish the overdose profile by strictly detailing the range of documented clinical consequences and the immediate emergency protocols required for patient safety. This structure defines the specific, state-verified risks of overexposure and mandates the urgent steps necessary to initiate management based on documented supportive and antidotal strategies.

Therapeutic Uses of Licoforte 4%

Licoforte 4% Uses and Benefits

Quick Facts: Therapeutic Domain
Indicated for: Gradual management of darkened skin areas
Treats: Melasma, chloasma (pregnancy mask), freckles, and age spots
Goal: Helps achieve a more uniform skin appearance

Licoforte 4% is a prescription topical formulation intended for the gradual management of hyperpigmented skin conditions. It is a treatment option used to address areas of skin that have become darkened due to increased melanin production.

This medication is specifically indicated for use in conditions such as melasma (dark, discolored patches on the skin, often on the face) and chloasma, which is often referred to as the pregnancy mask. It is also used to help lighten the appearance of other unwanted areas of melanin hyperpigmentation, including freckles and senile lentigines (age spots).

The therapeutic purpose of Licoforte 4% is to help the individual achieve a more even and uniform skin tone. Individuals should consult a healthcare professional to determine if this treatment is appropriate for their specific condition and to receive personalized usage instructions.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Licoforte 4% — official regulatory information


Eligibility Scope

Populations for whom use is allowed (as stated in label): Adults and adolescents aged 12 years and older for the indicated hyperpigmentation disorders.

Populations for whom use is contraindicated: Individuals with a prior history of sensitivity or allergic reaction to Hydroquinone or to any other ingredient in the specific formulation.

Age-related eligibility rules: Safety and effectiveness have not been established in pediatric patients under 12 years of age.

Pregnancy and lactation eligibility status: Use during pregnancy is classified as Category C by the FDA, meaning it should be given only if clearly needed. Caution must be exercised for nursing mothers, as it is not known if the drug is excreted into human milk.

Eligibility-related restrictions: The product must not be used by individuals with a known sulfite allergy if the formulation contains sodium metabisulfite, a preservative that may cause severe allergic reactions.


Eligibility Classifications (High-Level)

Eligibility severity classification: Contraindicated (Hypersensitivity); Use Not Established (Pediatric < 12 years); Caution/Restricted (Pregnancy/Lactation).

Regulatory basis: Primarily based on U.S. FDA Prescribing Information and European marketing authorizations.


Resulting Eligibility Structure

Official eligibility statements:

  • Licoforte 4% is contraindicated in patients with a history of sensitivity to its components.
  • Use is not established for children under the age of 12.
  • Use during pregnancy and lactation requires specific regulatory caution.

Connection to the overall eligibility profile: Official government documents establish eligibility based on absolute prohibitions defined by hypersensitivity to the formulation. Further limitations define who must not use the medicine due to insufficient data, such as children under 12, or who requires specific caution, such as pregnant or nursing women.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Licoforte 4% (Hydroquinone 4%) is focused on localized, topical effects, as systemic drug-drug interactions involving enzymes or transporters are not described in the official labeling due to minimal systemic absorption. This interaction structure is defined by two primary domains: pharmacodynamic reinforcement and chemical product-to-product reactions.


Documented Interaction Categories

Interacting Substance Interaction Type Regulatory Restriction
Photosensitizing Medications Pharmacodynamic Reinforcement Caution on concomitant use
Peroxide Products Chemical Reaction (Staining) Timing Separation Required

Official Interaction Statements

The prescribing information includes a specific caution regarding the concurrent use of other medicinal products known to be photosensitizing agents. This pharmacodynamic interaction may increase the risk of localized topical effects, such as irritation or phototoxicity, on the treated skin areas.

Additionally, Licoforte 4% reacts chemically with common peroxide-containing topical substances, including Benzoyl Peroxide and Hydrogen Peroxide. This documented chemical reaction results in a temporary, visible darkening or staining of the skin. To prevent this outcome, regulatory constraints establish a timing-based condition: the application of Licoforte 4% and any peroxide products must be strictly separated.

Mechanism of Action

How Licoforte 4% Works

Licoforte 4% functions as a depigmenting agent through its primary constituent, Hydroquinone, which selectively accumulates in melanocytes within the epidermis. This compound acts as a competitive inhibitor of the enzyme tyrosinase. Tyrosinase is the rate-limiting enzyme that catalyzes the initial steps of melanogenesis—the conversion of tyrosine to 3,4-dihydroxyphenylalanine (DOPA), and subsequently, DOPA to DOPAquinone .

By inhibiting tyrosinase, Hydroquinone disrupts the molecular cascade necessary for the biosynthesis of the pigment melanin. This targeted disruption leads to a reduction in the overall rate of melanin production within the affected cells. Additionally, the compound is thought to promote the accelerated degradation of melanosomes, which are the organelles responsible for synthesizing, storing, and transporting melanin. The overall physiological consequence is the modulation of pigment synthesis, limiting the amount of new melanin generated and transferred to keratinocytes.

Dosage and Administration Information

How to Use Licoforte 4% — Official Administration Guidelines

Licoforte 4% is a specialized pharmaceutical preparation intended strictly for topical use, applied directly to the skin. The official administration guidelines define a precise schedule and specific conditions for its correct use.


Element Official Instruction
Route of administration Topical (for external, cutaneous use only).
Dosing schedule Apply a thin layer to the affected areas and rub in well.
Frequency pattern Twice daily (morning and before bedtime).
Age-group rules Safety and effectiveness have not been established for patients under 12 years of age.
Procedural conditions Application must be limited to relatively small areas; sunscreen (SPF 15 or greater) or protective clothing is mandatory.

Resulting Procedural Structure

The application sequence is designed for consistent dermal delivery. The official regimen mandates the application of the 4% formulation twice daily, followed by thorough rubbing into the hyperpigmented area. This course of use requires continuous sun protection throughout the treatment period. Furthermore, the protocol includes a mandatory time constraint: if no lightening effect is observed after two months of use, the regimen must be discontinued.

This set of instructions establishes a standardized regimen focused on precise topical frequency and application scope. Adherence to these strict rules frames the entire course of use for Licoforte 4%.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Licoforte 4%


Evidence for Use in Melasma

The research base primarily consists of Randomized Controlled Trials (RCTs), where people were assigned by chance to use Licoforte 4%, a placebo (a non-active cream), or another active treatment. These RCTs are used in research to explore short-term symptom changes and evaluate different treatment approaches under controlled conditions. The studies included diverse adult populations, often focusing on individuals with varying degrees of melasma severity and different skin types.

Studies explored how symptoms evolved in the observed populations by using standardized clinical instruments, such as the Melasma Area and Severity Index (MASI), and global assessments by healthcare professionals. Research highlights changes measured during the study period, focusing on the appearance of the hyperpigmented areas over defined time intervals. Some trials described measurements of changes in the visible appearance of the darkened patches compared to the initial observations.

Evidence for Other Localized Hyperpigmentation

Licoforte 4% was also studied for use in other types of unwanted hyperpigmentation, such as senile lentigines (commonly called age spots) and freckles. Research examined these conditions through smaller clinical trials and case series which focused on localized areas of skin discoloration. Studies in this category explored outcomes related to visible changes by evaluating changes in the size and color intensity of the specific lesions.

The available data for these specific, localized conditions remains less extensive. Compared to the extensive research available for melasma, there are fewer large-scale Randomized Controlled Trials dedicated solely to age spots or freckles. Subgroup findings are uncertain, and results often rely on a smaller pool of focused data.


Research Gaps and Areas of Uncertainty

The evidence highlights what is known—and what is still uncertain—about the medicine. Follow-up durations were limited, as primary efficacy evaluations rarely extended beyond 3 to 6 months post-treatment. Clinical literature includes reports that for melasma, the skin has a tendency to repigment, and recurrence is a common observation in the studied populations.

The research also notes that findings describe group patterns under the specific condition that the patient also uses strict, concurrent sun protection. The evidence does not fully establish the response without this co-administered step. Comparative evidence is lacking for many patient subgroups, and data for special populations, such as children and pregnant individuals, remain insufficient.

Key Studies & References

  1. HYDRO-Q® (Hydroquinone 4%) Gel - DailyMed (FDA Labeling and Indications)

Frequently Asked Questions (FAQ)

Common questions about Licoforte 4% (FAQ)

Q: Is Licoforte 4% an antibiotic or a steroid?

According to the official product information, Licoforte 4% is classified as a Depigmenting Agent that reduces the production of the pigment melanin. It is not an an antibiotic, which fights bacteria, nor is it a steroid (corticosteroid).


Q: How quickly does Licoforte 4% typically start working?

The official administration guidelines focus on a defined evaluation period rather than immediate onset. They state that the product should be discontinued if no lightening effect is observed after two months of use. The expected timeline for the start of the lightening effect is not specifically defined in the official prescribing information.


Q: Can Licoforte 4% be used on the face or sensitive areas?

Regulatory information advises that the product is for external, topical use only and that application should be limited to relatively small areas. It is explicitly advised to avoid contact with the eyes and mucous membranes.


Q: What kind of studies support the use of Licoforte 4%?

Studies and official information indicate that the product is primarily supported for the gradual lightening of various hyperpigmented skin conditions. These conditions include specific types of discoloration like chloasma, melasma, freckles, and senile lentigines (commonly known as age spots).


Q: Can I use Licoforte 4% on broken or infected skin?

Official precautions advise that the product should not be applied to cut, abraded, sunburned, or wounded skin in the area of application. A test for skin sensitivity on a small, unbroken patch of skin is described as a regulatory precaution before beginning treatment.


Q: What are the signs of an allergic reaction to Licoforte 4%?

Allergic-type reactions documented in official sources include skin rash, itching, hives, and swelling of the face, lips, tongue, or throat (anaphylactic symptoms). Less severe reactions, such as localized contact dermatitis, have also been reported.


Q: Can Licoforte 4% be used with other topical creams at the same time?

Official labeling requires strict separation from peroxide-containing topical substances, such as Benzoyl Peroxide, to prevent a temporary skin-staining chemical reaction. However, most other cosmetics, sunscreens, and moisturizing lotions may be worn over the medication.


Q: Does using a moisturizer help when applying Licoforte 4%?

Since common local side effects include dryness and skin irritation, official patient information often describes that moisturizing lotions may be worn over this medication. This approach is often described in patient information alongside managing localized reactions such as dryness.


Q: Is Licoforte 4% available over the counter?

No. The 4% formulation of this product is classified by regulatory bodies as a prescription-only drug. This classification requires professional supervision during use.


Q: Is Licoforte 4% the same as other 'Lico-' name medications?

Licoforte 4% is chemically defined by its active ingredient, Hydroquinone, and its 4% concentration. Other products with similar names may contain different active ingredients, concentrations, or formulations, so the official labeling for Licoforte 4% only applies to this specific product.


Q: What is the difference between Licoforte 4% cream and Licoforte 4% ointment (assuming multiple forms exist)?

Official documentation states the product may be available as a Cream, Topical Solution, or Gel. Differences between these forms generally relate to their base ingredients (vehicle), which may affect skin feel, consistency, and how the active ingredient is delivered to the skin layers.


Q: Will Licoforte 4% show up on a drug test?

The product is not a controlled medication. Official labeling states that minimal systemic absorption is expected following topical use, and no systemic reactions have been reported. Given the minimal systemic absorption and non-controlled status, the substance is not typically detected in routine drug testing.


Q: Are there any food restrictions while using Licoforte 4%?

Because the product is for external use only with minimal systemic absorption, the official drug labeling does not describe any food restrictions or dietary changes that are necessary during the course of use.


Q: How long can a person typically use Licoforte 4% before needing a break?

The official maximum duration of treatment is not more than 6 months in any single case. This time constraint is designed to limit the potential risk of a serious side effect called Exogenous Ochronosis, which is associated with chronic, long-term use.


Q: Is it true that Licoforte 4% is a controlled substance?

No. The active ingredient, Hydroquinone 4% (the basis of Licoforte 4%), is not classified as a controlled medication by regulatory bodies.


Q: Are there any specific cosmetic products that interact with Licoforte 4%?

Yes. The official interaction statement focuses on peroxide-containing topical substances, which are often found in acne treatments and certain cosmetics. These must not be applied concurrently to prevent skin staining.


Q: Does Licoforte 4% help with itching?

Official documentation does not indicate this product is used to treat itching. Instead, itching (pruritus) is documented as a possible adverse reaction (side effect) or sign of a reaction to the product.


Q: Does Licoforte 4% make skin sensitivity worse?

Official documentation notes that the product may cause common local reactions like mild skin irritation, redness, stinging, or dryness. These effects are commonly reported. They may be more noticeable in individuals who have pre-existing skin sensitivity.


Q: Is Licoforte 4% manufactured with any common allergens?

Yes. The official labeling contains a prominent warning about the preservative sodium metabisulfite. This is a sulfite that may cause allergic-type reactions in susceptible people, especially those with pre-existing conditions like asthma.


Q: Can Licoforte 4% cause changes in skin color?

The product is associated with both its intended lightening action and the potential for unintended changes. The official warning describes a serious adverse reaction called Exogenous Ochronosis, which is a gradual blue-black darkening of the skin that may be permanent.


Q: Can using too much Licoforte 4% cause systemic side effects?

The official labeling states that no systemic reactions have been reported from the use of topical hydroquinone at the recommended dosage. Application is limited to small areas precisely to minimize the potential for exposure to the body's entire system.


Q: Is Licoforte 4% absorbed into the bloodstream?

Official labeling notes that minimal systemic absorption of the active ingredient occurs following topical administration. While a small amount may be absorbed, official labeling indicates that this quantity is minimal, and no systemic reactions have been reported when the product is used as directed.


Q: Why is Licoforte 4% only available as a prescription?

Regulatory bodies, including the FDA, determined that products with this concentration of hydroquinone are unapproved for over-the-counter (OTC) sale. This classification is due to potential risks, necessitating professional physician supervision.


Q: What happens if Licoforte 4% gets in my eyes?

Official product information advises users to avoid contact with eyes and mucous membranes. If accidental contact occurs, the affected area should be washed immediately with large amounts of water, and contacting a healthcare professional is advised if irritation persists.

How should Licoforte 4% be stored and disposed of?

Storage and Environmental Control

Licoforte 4% (Hydroquinone 4% Cream) must be stored at Controlled Room Temperature, defined as 20^circ to 25 C (68^circ to 77 F), with excursions permitted up to 30 C (86 F). The product must be kept tightly closed to protect it from air and light, and must not be frozen. Storage areas should avoid excessive heat.

Stability and Child Safety

The cream must be discarded immediately if it darkens to a brown or black color, which indicates chemical oxidation and instability. As a pharmaceutical product, Licoforte 4% must be kept out of the reach of children.

Disposal Instructions

Unused or expired medication must be disposed of according to local regulations. Consumers should not dispose of the cream by flushing it down a toilet or pouring it into a drain to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Licoforte 4% found in:

A-Z Index: